{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Questionnaire for Gastroenterologist

Dear Doctor,
The objective of this questionnaire is to obtain clinical insights to understand the need gap and place of Infliximab in the management of Crohn’s disease.
  1. How many patients of moderately to severely active Crohn’s colitis patients do you see in a month in your practice? *

  2. As per your experience how many moderately to severely active Crohn’s disease patients develop fistulating Crohn’s disease? *

  3. What modalities do you prefer to diagnose Crohn’s disease in your practice? (You can select multiple options)? *
  4. What are the parameters on which you assess the severity of Crohn’s disease? *

  5. What is the preferred molecule for the management of moderately to severely active Crohn’s disease in your practice? *

  6. What is the preferred molecule for the management of fistulating Crohn’s disease in your practice? *

  7. How early do you get the desired results with infliximab in the management of fistulating Crohn’s disease? *

  8. Do you get patients with relapse and flares of Crohn’s disease after discontinuation of infliximab? *

  9. If response to question 8 is “Yes” than what is the proportion of patients in your practice who present with relapse and flares after discontinuation of infliximab? *

  10. Do you use the same anti-TNF α agent for the treatment if patient presents with relapse and flares after discontinuation of that anti-TNF α agent? *

  11. If response to question 10 is “No” what is your preferred approach for managing such patients? *

  12. What are the commonly observed adverse drug reactions of Infliximab in your practice? *